达格列净对不稳定心绞痛合并2型糖尿病患者冠脉介入治疗后心功能、炎症反应及心血管结局的影响

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (503 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Dapagliflozin on cardiac function,inflammatory response and cardiovascular outcome in patients with unstable angina(UA)combined with type 2 diabetes(T2DM)after percutaneous coronary intervention(PCI).Methods A total of 70 patients with UA combined with T2DM who underwent PCI in Liaoyang Central Hospital from September 2018 to September 2019 were selected as the research subjects,and they were divided into an observation group and a control group by random number table method,each with 35 cases.Both groups of patients were treated with conventional drugs.On this basis,patients in the observation group were treated with Dapagliflozin to control blood sugar and patients in the control group were treated with hypoglycemic drugs other than sodium-glucose cotransporter 2(SGLT-2)inhibitor.Both groups were treated continuously for 24 weeks.The differences in left ventricular end diastolic diameter(LVEDD),left ventricular end systolic diameter(LVESD),left ventricular ejection fraction(LVEF),inflammatory factor levels before and after treatment and major adverse cardiovascular events(MACE)between the two groups were analyzed.Results After treatment,LVEF of observation group was higher than that of control group,LVESD and LVEDD of observation group were lower than those of control group,the differences were statistically significant(P＜0.05).After treatment,the levels of C-reactive protein(CRP),interleukin 6(IL-6),tumor necrosis factor-α(TNF-α)of observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).During the treatment period,there were no significant differences in the incidence rates of cardiogenic death,recurrent myocardial infarction and other adverse cardiovascular events between the two groups of patients(P＞0.05),but the incidence rates of severe arrhythmia and heart failure in the observation group were lower than those of the control group,the differences were statistically significant(P＜0.05).Conclusion Dapagliflozin treatment for patients with UA combined with T2DM after PCI can improve heart function to a certain extent,reduce the levels of inflammatory factors as well as the incidence of MACE.

Key words： Unstable angina Type 2 diabetes Percutaneous coronary intervention Dapagliflozin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Gang

Cite this article:

ZHANG Gang. Effect of Dapagliflozin on cardiac function，inflammatory response and cardiovascular outcomes in patients with unstable angina pectoris and type 2 diabetes after percutaneous coronary intervention[J]. 中国当代医药, 2022, 29(10): 57-61.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I10/57

[10]	国家卫生计生委合理用药专家委员会，中国药师协会.冠心病合理用药指南（第2 版）[J].中国医学前沿杂志（电子版），2018，10（6）：1-130.
[11]	中华医学会糖尿病学分会.中国2 型糖尿病防治指南（2017年版）[J].中国实用内科杂志，2018，38（4）：292-344.
[1]	McMurray JJV，Ponikowski P，Bolli GB.Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure：a randomized placebo-controlled trial[J].JACC Heart Fail，2018，6（1）：8-17.
[2]	Samman Tahhan A，Sandesara P，Hayek SS.High-Sensitivity Troponin I Levels and Coronary Artery Disease Severity，Progression，and Long-term Outcomes[J].JAm Heart Assoc，2018，7（5）：e007914.
[3]	Mishriky BM，Tanenberg RJ，Sewell KA.Cummings DM Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an addon therapy to metformin in patients with type 2 diabetes：A systematic review and meta-analysis[J].Diabetes Metab，2018，44（2）：112-120.
[4]	Harding SD，Sharman JL，Faccenda E.The IUPHAR/BPS Guide to PHARMACOLOGY in 2018：updates and expansion to encompass the new guide to IMMUNOPH ARMA COLOGY[J].Nucl Acids Res，2018，46（D1）：D1091-D1106
[5]	Neal B，Perkovic V，Mahaffey KW.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med，2017，377（7）：644-657.
[6]	Ike A，Nishikawa H，Shiraik K，et al.Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention-from the FU-registry[J].Circ J，2011，75（4）：791-799.
[7]	Accord Study Group，Gerstein HC，Miller ME，et al.Longterm effects of intensive glucose lowering on cardiovascular outcomes[J].N Engl J Med，2011，364（9）：818-828.
[8]	Leng W，Ouyang X，Lei X.The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE（-/-）mice[J].Mediators Inflamm，2016，26（2）：120-128.
[9]	Jabbour S，Seufert J，Scheen A，et al.Dapagliflozin in patients with type 2 diabetes mellitus：A pooled analysis of safety data from phase Ⅱb/Ⅲclinical trials[J].Diabetes Obes Metab，2018，20（3）：620-628.
[12]	Karavaglar E，Akgun AN，Muderrisoglu IH，et al.Coronary angiography for follow-up of heart transplant recipients：usefulness of the gensini score[J].Exp Clin Transplant，2020，18（S1）：99-104.
[13]	Everett BM，Brooks MM，Bhatt DL.Troponin in stable ischemic heart disease and diabetes[J].N Engl J Med，2015，373（20）：1978-1979.
[14]	Gaede P，Oellgaard J，Carstensen B.Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria：21 years follow-up on the Steno-2 randomised trial[J].Diabetologia，2016，59（11）：2298-2307.
[15]	Tancredi M，Rosengren A，Svensson AM.Excess mortality among persons with type 2 diabetes[J].N Engl J Med，2016，374（8）：788-789.
[16]	Scirica BM，Braunwald E，Raz I.Heart failure，saxagliptin，and diabetes mellitus：observations from the SAVOR-TIMI 53 randomized trial[J].Circulation，2014，130（18）：1579-1588.
[17]	Endler G，Klimesch A，Sunder-Plassmann H.Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease[J].Br J Haematol，2002，117（2）：399-404.
[18]	岳晓燕，张大卫.利拉鲁肽在2 型糖尿病合并急性ST 段抬高型心肌梗死患者PCI 术后的应用体会[J].国际医药卫生导报，2018，24（23）：3613-3616.
[19]	王国余，刘玲，王叶宝，等.MSI 对行急诊介入治疗的老年ST 段抬高型STEMI 患者预后的预测价值[J].中国老年学杂志，2020，40（14）：2924-2926.
[20]	肖莲，何元军，刘利君.替罗非班对ASTEMI 患者PCI 术后冠脉血流、心功能及炎性因子的影响[J].心血管康复医学杂志，2020，29（3）：321-325.
[21]	Bonora BM，Avogaro A，Fadini GP.Extraglycemic Effects of SGLT2 Inhibitors：A Review of the Evidence[J].Diabetes Metab Syndr Obes，2020，13：161-174.
[22]	Wiviott SD，Raz I，Bonaca MP，et al.Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes[J].N Engl J Med，2019，380（4）：347-357.
[23]	宋青青，黄春，黄云飞，等.达格列净对2 型糖尿病合并慢性心力衰竭患者IL-6、左室舒张功能的影响[J].中国医药科学，2021，11（16）：76-79，128.
[24]	陈耿钦.达格列净对2 型糖尿病合并代谢综合征患者糖脂代谢和氧化应激指标的影响[J].中国医药科学，2021，11（3）：119-122.
[25]	宋青青，劳斌昌，黄春，等.达格列净对2 型糖尿病合并肥胖患者脂联素与瘦素水平影响[J].现代医院，2020，20（8）：1215-1217，1220.
[26]	吴承杰.达格列净治疗糖尿病合并心力衰竭的疗效及对降低炎性因子水平和心力衰竭恶化再入院率的影响[J].中国医药科学，2021，11（24）：100-103，110.